Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
MannKind Corporation (NASDAQ:MNKD)’s future hangs on whether Afrezza, its inhaled insulin, will ever catch on. If the company’s stock price movement is any indication, Wall Street doesn’t seem to think so. However, Jeffries analysts think the drug will fill a big gap that currently exists in diabetes treatment. As a result, they have initiated coverage of the company with a Buy rating and $10 per share price target, which represents an upside of about 34%.
http://www.valuewalk.com/2014/08/mannkind-corporation-not-everyones-bearish-on-afrezza/
My prediction? It will bomb 😱
http://www.valuewalk.com/2014/08/mannkind-corporation-not-everyones-bearish-on-afrezza/
My prediction? It will bomb 😱